Dr. Pavol Čekan, CEO of MultiplexDX, recently became Honorary Consul of the Republic of Iceland.
Multiple factors have pushed Iceland as a favorite destination for biosciences and biotechnology companies while it appears to present the right conditions for setting up research units and carrying on production in this sector. It’s a nation that’s very proud of its highly educated workforce and another critical factor in the biotech domain is strong government support. The Government of Iceland has a strong historical relationship with the biotech industry, which keeps getting strengthened each year.
Therefore, Dr. Pavol Čekan, an alumnus of the University of Iceland, founder, CEO & CSO of MultiplexDX, and recently appointed Honorary Consul of Iceland in the Slovak Republic is excited to share his recent appointment.
“I am looking forward to supporting scientific, economic, and cultural interactions between Iceland and Slovakia in the coming future."
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.